Results 1 to 10 of about 2,886,292 (384)
The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease. [PDF]
PLoS One, 2017 Background/Aims Since the degeneration of the nigrostriatal dopaminergic pathway in Parkinson’s disease (PD) is associated with the inflammation process and decreased levels of cyclic nucleotides, inhibition of up-regulated cyclic nucleotide ...
Schwenkgrub J +5 more
europepmc +2 more sources
Effectiveness of Phosphodiesterase-5 Inhibitor Therapy for Portopulmonary Hypertension
Canadian Respiratory Journal, 2015 BACKGROUND: Portopulmonary hypertension is associated with significant morbidity and mortality. Phosphodiesterase-5 inhibitor therapy is efficacious in other causes of WHO group I pulmonary arterial hypertension.
Jolene H Fisher +4 more
doaj +2 more sources
Phosphodiesterase Inhibitor‐Based Vasodilation Improves Oxygen Delivery and Clinical Outcomes Following Stage 1 Palliation [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016 BackgroundSystemic vasodilation using α‐receptor blockade has been shown to decrease the incidence of postoperative cardiac arrest following stage 1 palliation (S1P), primarily when utilizing the modified Blalock‐Taussig shunt.
Kimberly I. Mills +13 more
doaj +2 more sources
Theophylline and phosphodiesterase inhibitors [PDF]
European Respiratory Journal, 1995 Michel Aubier, Peter J. Barnes
openalex +4 more sources
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.
New England Journal of Medicine, 2022 BACKGROUND Phosphodiesterase 4 (PDE4) inhibition is associated with antiinflammatory and antifibrotic effects that may be beneficial in patients with idiopathic pulmonary fibrosis.
L. Richeldi +9 more
semanticscholar +1 more source
British Journal of Dermatology, 2021 In atopic dermatitis (AD), phosphodiesterase 4 (PDE4) inhibition reduces proinflammatory mediators and cytokines. Difamilast is a new selective PDE4 inhibitor.
H. Saeki +4 more
semanticscholar +1 more source
Phosphodiesterase inhibitors [PDF]
British Journal of Pharmacology, 2006 Phosphodiesterases are a diverse family of enzymes that hydrolyse cyclic nucleotides and thus play a key role in regulating intracellular levels of the second messengers cAMP and cGMP, and hence cell function. Theophylline and papaverine have historically been used therapeutically and are known to be weak inhibitors of PDE, but to what extent this ...
Boswell-Smith, V, Spina, D, Page, C P
openaire +4 more sources
Turkderm Turkish Archives of Dermatology and Venereology, 2022 Apremilast is an orally used small-molecule inhibitor of phosphodiesterase-4. It has been approved for the treatment of adult patients with psoriatic arthritis and moderate to severe plaque psoriasis.
Nihal Kundakçı
doaj +1 more source
Journal of International Medical Research, 2021 Objective To investigate the therapeutic effect of implanting a three-piece inflatable penile prosthesis (IPP) combined with the phosphodiesterase-5 inhibitor sildenafil in severe erectile dysfunction (ED) patients.
Jian Wang +6 more
doaj +1 more source
Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. [PDF]
PLoS ONE, 2010 The purpose of the present study was to investigate whether cilostazol, a phosphodiesterase-III inhibitor and antiplatelet drug, would prevent tPA-associated hemorrhagic transformation.
Mitsunori Ishiguro +10 more
doaj +1 more source